Blood NeoplasiaGenomicsPeer-reviewed journal article
Single-Cell Multiomics Reveals Regulatory Mechanisms of CAR T Cell Persistence and Dysfunction in Multiple Myeloma
Lorea Jordana-UrrizaiD, Guillermo SerranoiD, Sergio Camara-Peña, María Eréndira Calleja-CervantesiD, Patxi San Martín‐ÚriziD, Aintzane ZabaletaiD, Aina Oliver‐CaldésiD, Marta Español‐RegoiD, Diego AlignaniiD, Teresa LozanoiD, Saray Rodríguez-DiaziD, Elena IglesiasiD, V. CabañasiD, Juan Luis RegueraiD, Verónica González‐CalleiD, Maria V. MateosiD, Fermin Sanchez-GuijoiD, Bruno PaivaiD, Juan José LasarteiD, Susana InogésiD, Ascensión López-Dı́az de CerioiD, Europa Azucena González‐NavarroiD, Manel JuaniD, Carlos Fernández de LarreaiD, Luis‐Esteban Tamariz‐AmadoriD, , Felipe PrósperiD
Abstract
Understanding the mechanisms that drive chimeric antigen receptor (CAR) T cell function and persistence in multiple myeloma (MM) remains a critical challenge for improving therapeutic outcomes. In this study, we applied single-cell multiomics and gene regulatory network (GRN) analysis to characterize the transcriptional dynamics and clonal evolution of BCMA-targeted CAR T cells in longitudinally collected bone marrow (BM) and peripheral blood (PB) samples from MM patients. Our results revealed that CAR T cells infiltrating BM exhibited a more activated and exhausted phenotype compared to their PB counterparts, with key transcriptional regulators driving these changes. Dysregulation in the effector-to-memory transition led to an increased presence of terminally differentiated CAR T cells, correlating with poor persistence. Additionally, we identified a hyperexpanded CAR T clone in the BM of a patient with partial response, marked by elevated IL10 expression. Functional analyses demonstrated that stimulation of endogenous TCR enhanced IL10 production, potentially contributing to impaired CAR T cell proliferation and persistence. These findings uncover critical regulatory mechanisms influencing CAR T cell dynamics, offering new insights into improving CAR T cell persistence and therapeutic efficacy in MM and highlights potential molecular targets for optimizing CAR T cell therapy in patients with MM.
- organism: human
- assay: scRNA-seq
- assay: multiome
- research focus: gene regulatory network inference
- approach: statistical model
- Citations
- 6
- FWCI
- 15.02
- Field percentile
- top 1%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Rational engineering of sdAb-based CAR T cells targeting BCMA enhances antitumor efficacy and persistence in Multiple Myeloma
Vianca Ibarra-Garcia, María Eréndira Calleja-Cervantes, … Felipe Prósper·bioRxiv·Jun 5, 2026
- Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma
E. Zah, E. Nam, … Y. Y. Chen·bioRxiv·Mar 12, 2020
- Endogenous CD28 drives CAR T cell responses in multiple myeloma
M. M. Lieberman, J. H. Tong, … S. H. Olejniczak·bioRxiv·Mar 21, 2024
- In vivo CRISPR screens identify key modifiers of CAR T cell function in myeloma
Nelson H. Knudsen, Giulia Escobar, … Marcela Valderrama Maus·NaturePeer-reviewed·Sep 24, 2025
- Rapid BCMA downmodulation on myeloma cells upon CAR T cell contact is mediated by trogocytosis and BCMA internalization
N. Camviel, B. Wolf, … C. Arber·bioRxiv·Jul 23, 2022
- Multi-Niche Human Bone Marrow On-A-Chip for Studying the Interactions of Adoptive CAR-T Cell Therapies with Multiple Myeloma
D. Ghoshal, I. Petersen, … K. Roy·bioRxiv·Apr 8, 2024